Список проголосовавших за комментарий " On The Wires<ul><li>Intec Pharma Ltd. (<strong>NTEC</strong>) announced the initiation of a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed by Intec for various indications, including low back pain and Fibromyalgia. Expects Phase I Results in the Third Quarter of 2017.</li><li>Cubic Mission Solutions, a business division of Cubic Corporation (<strong>CUB</strong>), announced a contract award worth more than $20 million from the U.S. Navy's San Diego-based Space and Naval Warfare Systems Command (SPAWAR) for the development and delivery of Person-portable Common Data Link (PCDL) systems. Cubic will deliver these systems for the Navy Tactical Mobile (TacMobile) Program, which is managed by the Carrier and Air Integration Program Office, or PMW 750. The TacMobile Program provides expeditionary ground support for Maritime Patrol and Reconnaissance Aircraft (MPRA), which include the P-3C, P-8A aircraft and the MQ-4C Triton. PMW 750 is responsible for providing integrated Command, Control, Communications, Computers and Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities in support of these Navy aircraft. Under the contract, Cubic will be responsible for procuring, producing, assembling, testing, documenting and delivering TacMobile PCDL. </li><li>AVEO Oncology (<strong>AVEO</strong>) announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo (nivolumab), in advanced renal cell carcinoma (RCC). The study, which will be led by the Institut Gustave Roussy in Paris, is under the direction of Professor Bernard Escudier, MD, Chairman of the Genitourinary Oncology Committee. The Phase 1 trial will evaluate the safety of tivozanib in combination with nivolumab at escalating doses of tivozanib and, assuming favorable results, is expected to be followed by an expansion Phase 2 cohort at the established combination dose.</li><li>EDF Group (<strong>ECIFY</strong>), via its subsidiary EDF Energies Nouvelles has joined the Masdar-led consortium developing the 800-megawatt (MW) third phase of the Mohammed bin Rashid Al Maktoum Solar Park in Dubai.</li></ul>"